GLAXO.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 06:00):

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally...

Stats
Today's Volume	87 380.00
Average Volume	155 822
Market Cap	334.73B
EPS	INR0 ( 2024-02-11 )
Next earnings date	( INR0 ) 2024-05-14
Last Dividend	INR32.00 ( 2023-06-30 )
Next Dividend	INR0 ( N/A )
P/E	63.21
ATR14	INR2.82 (0.14%)

Volume Correlation

Long: -0.21 (neutral)

Short: 0.83 (strong)

Signal:(57.036) Same movement expected

GlaxoSmithKline Correlation

10 Most Positive Correlations
DALALSTCOM.NS	0.832

10 Most Negative Correlations
LTGILTBEES.NS	-0.83
ANANDRATHI.NS	-0.821
KPIGLOBAL.NS	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlaxoSmithKline Correlation - Currency/Commodity

0.90
( strong )

0.91
( very strong )

-0.10
( neutral )

0.53
( weak )

-0.86
( strong negative )

-0.46
( neutral )

GlaxoSmithKline Financials

Annual	2022
Revenue:	INR32.52B
Gross Profit:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Revenue:	INR32.52B
Gross Profit:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Revenue:	INR32.78B
Gross Profit:	INR18.28B (55.78 %)
EPS:	INR22.48

FY	2021
Revenue:	INR31.99B
Gross Profit:	INR18.04B (56.40 %)
EPS:	INR21.14

Financial Reports:

No articles found.

GlaxoSmithKline Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR32.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

GlaxoSmithKline Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.28 - low (42.21%) | Divividend Growth Potential Score: 5.12 - Stable (2.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.50	2003-04-10
Last Dividend	INR32.00	2023-06-30
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR435.25	--
Avg. Dividend % Per Year	1.67%	--
Score	2.79	--
Div. Sustainability Score	4.28
Div.Growth Potential Score	5.12
Div. Directional Score	4.70	--

Next Divdend (Est)
(2025-04-07)

INR32.69 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.79

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR17.50	1.50%
2019	INR20.00	1.34%
2020	INR20.00	1.23%
2021	INR30.00	1.86%
2022	INR60.00	3.45%
2023	INR32.00	2.43%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SONATSOFTW.NS	Dividend Knight	2023-07-21	Semi-Annually	23	1.92%
MOIL.NS	Dividend Knight	2023-09-08	Semi-Annually	14	2.38%
HDFCBANK.NS	Dividend Junior	2023-05-16	Annually	28	0.58%
BHANDARI.NS	Dividend Junior	2023-09-22	Annually	8	0.18%
RALLIS.NS	Dividend Junior	2023-05-30	Annually	23	0.94%
KIRLOSIND.NS	Dividend Junior	2023-08-03	Annually	17	0.72%
ENDURANCE.NS	Dividend Junior	2023-08-10	Annually	8	0.30%
ALBERTDAVD.NS	Dividend Junior	2023-08-02	Annually	8	1.24%
SUTLEJTEX.NS	Dividend Junior	2023-08-18	Annually	18	1.03%
NCLIND.NS	Dividend Junior	2023-09-15	Semi-Annually	18	1.25%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.160	1.500	6.81	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.322	1.500	7.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	519.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.24	2.00	6.88	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.604	1.000	3.27	3.27	[0.2 - 0.8]
operatingProfitMarginTTM	0.264	1.000	6.73	6.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	64.39	1.000	3.60	0	[1 - 100]
returnOnEquityTTM	0.322	2.50	8.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.592	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.067	1.500	6.22	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0319	1.000	-1.702	0	[0.1 - 0.5]
Total Score				5.12

GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Realtime updates for GlaxoSmithKline [GLAXO.NS]

Upcoming Earnings Alert

GlaxoSmithKline Dividend Information - Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)